Presentation (CTI)

OBJECTIVES: Published reimbursement decisions from 2024 and 2025 were reviewed across 14 global HTA markets. For each year, data was extracted on the number of distinct assessed products, targeted indications, and reimbursement outcomes. Cross-market variation was assessed using matched HTA submissions, defined as cases where the same product and indication were reviewed by multiple HTA bodies. These submissions were analysed to determine the extent of divergence in reimbursement outcomes over the two-year period.
METHODS: Published reimbursement decisions from 2024 and 2025 were reviewed across 14 global HTA markets. For each year, data was extracted on the number of distinct assessed products, targeted indications, and reimbursement outcomes. Cross-market variation was assessed using matched HTA submissions, defined as cases where the same product and indication were reviewed by multiple HTA bodies. These submissions were analysed to determine the extent of divergence in reimbursement outcomes over the two-year period.
RESULTS: In 2025, the mean successful reimbursement rate across countries was 86%, representing an increase from 82% in 2024. Although success rates varied considerably across countries, most markets remained broadly consistent over the two-year period. Furthermore, for matched submissions across different markets, the likelihood of achieving the same outcome remained steady across the two-year period at 61%. However, the volume of reimbursement decisions decreased substantially, from n=2,293 in 2024 to n=1,193 in 2025, with the largest declines observed in Italy (-594), France (-222), Australia (-135), and Spain (-81).
CONCLUSIONS: While the long-term implications of global policy shifts for patient access remain uncertain, particularly as wider effects of policies such as MFN continue to emerge, the likelihood of successful reimbursement remained consistent between 2024 and 2025. However, marked reductions in the number of reimbursement decisions in certain countries may indicate hesitancy among pharmaceutical developers to submit in markets that could become key targets for MFN reference pricing.